ADCT (ADC Therapeutics) Common Stock : $8.44 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Common Stock?

ADC Therapeutics's quarterly common stock increased from Sep. 2024 ($8.23 Mil) to Dec. 2024 ($8.43 Mil) and increased from Dec. 2024 ($8.43 Mil) to Mar. 2025 ($8.44 Mil).

ADC Therapeutics's annual common stock stayed the same from Dec. 2022 ($7.31 Mil) to Dec. 2023 ($7.31 Mil) but then increased from Dec. 2023 ($7.31 Mil) to Dec. 2024 ($8.43 Mil).

ADC Therapeutics Common Stock Historical Data

The historical data trend for ADC Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Common Stock Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

6.31

6.45

7.31

8.43

ADC Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Common Stock	Get a 7-Day Free Trial															7.31	8.23	8.23	8.43	8.44

ADC Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

ADC Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).